Abstract
ABSTRACT: Hypertension is a well-established independent risk factor for cardiovascular diseases and stroke. Valsartan is an angiotensin II receptor antagonist used in the management of hypertension. Valsartan is rapidly absorbed following oral administration. Many conventional oral formulations for hypertension offer convenience and ease of use but produce unreliable blood levels and inconsistent response. Buccal route offers several advantages such as rapid absorption, by-passing first pass metabolism and higher blood levels due to high vascularisation of the region and prolonged duration of action. Hence, in the present work mucoadhesive buccal tablets of Valsartan were prepared with the objective of avoiding first pass metabolism and prolonging the duration of action.
References
Jain NK, Oral transmucosal drug delivery. CBS Publishers and Distributors. New Delhi: 2002; 52-81.
Kaplan NM. Systemic hypertension: Treatment. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2011: chap 46.
Brunton LL, Lazo JS, Parker KL. The Pharmacological Basis of therapeutics. 11th ed. USA. McGraw-Hill Company 2006; p.812-14-59- 60.1883
Gupta KR, Wadodkar AR, Wadodkar SG. UV Spectrophotometric methods for estimation of Valsartan in bulk and tablet dosage form. Int J ChemTech. Res 2010; 2(2): 985-89
Miyazaki S, Nakayama M, Oda M, Takada M, Attwood D, Drug release from oral mucosive adhesive tablets of chitosan and sodium alginate. Int. J. Pharm. 1995; 118: 257-263.
Shojaei AH, Systemic drug delivery via the buccal mucosal route. Pharm Tech. 2001; 79-81
Marcos BP, Iglesias R, Gomez AC, Mechanical and drug release properties of atenolol carbomer hydrophilic matrix tablet. J Control Rel. 1991; 17: 267-276
Velmurugan. S, Deepika. B, Nagaraju. K, Sundar Vinushitha, Formulation and in-vitro evaluation of buccal tablets of piroxicam. Int J PharmTech Res. 2010; 2(3): 1958-1968.
Varshosaz J, Dehghan Z. Development and characterization of buccoadhesive nifedipine tablets. Eur J Pharm Biopharm. 2002; 54: 135-41.
Velmurugan S, Srinivas P. Formulation and In vitro evaluation of losartan potassium mucoadhesive buccal tablets. Asian J Pharm Clin Res. 2013; 6: 125-30.
Vaidya VM, Manwar JV, Mahajan NM, Sakarkar DM. Design and In-vitro evaluation of mucoadhesive buccal tablets of terbutaline sulfate. Int J Pharm Tech Res. 2009; 1: 588-97.
How to cite this article:
Mathur R, Tamrakar B, Anita, Lal B, Mafidar R, Bhowmick M and Rathi J. Design and evaluation of Mucoadhesive Buccal Tablets of an anti-hypertensive drug- Valsartan. Int. J. Res. Dev. Pharm. L. Sci. 2018; 7(5): 3110-3114. doi: 10.13040/IJRDPL.2278-0238.7(5).3110-3114
This Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array